CRC-话题@MedSci

#CRC#

70篇内容 | 1951人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1827234, encodeId=bd7a182e2345a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Ann Intern Med：阿司匹林、NSAIDS与降低患CRC风险相关, objectType=article, longId=55365, objectId=f96a55365c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96a55365c5, replyNumber=0, likeNumber=45, createdTime=2015-09-20, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96a55365c5, moduleTitle=Ann Intern Med：阿司匹林、NSAIDS与降低患CRC风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96a55365c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827233, encodeId=dd2a182e23321, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, objectType=article, longId=51425, objectId=80e15142500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e15142500, replyNumber=0, likeNumber=31, createdTime=2015-07-18, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e15142500, moduleTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e15142500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827231, encodeId=8d47182e231e4, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=现代临床研究亟待发展的一个角色：CRC, objectType=article, longId=43913, objectId=99c64391372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99c64391372, replyNumber=0, likeNumber=27, createdTime=2015-10-24, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99c64391372, moduleTitle=现代临床研究亟待发展的一个角色：CRC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99c64391372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827230, encodeId=0e4a182e230df, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=30, createdTime=2015-08-03, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, objectType=article, longId=34270, objectId=a77a342e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77a342e036, replyNumber=0, likeNumber=25, createdTime=2014-08-07, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77a342e036, moduleTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a77a342e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827227, encodeId=ac92182e2272a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=ASCO 2014：荟萃分析显示5FU一线双药化疗改善老年CRC的PFS, objectType=article, longId=35258, objectId=418835258dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=418835258dd, replyNumber=0, likeNumber=24, createdTime=2014-05-27, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=418835258dd, moduleTitle=ASCO 2014：荟萃分析显示5FU一线双药化疗改善老年CRC的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=418835258dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827226, encodeId=0b5d182e226cd, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, objectType=article, longId=35106, objectId=224f351069b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=224f351069b, replyNumber=0, likeNumber=44, createdTime=2015-04-08, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=224f351069b, moduleTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=224f351069b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827232, encodeId=c106182e2321a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=2015年CRC行业的发展前景, objectType=article, longId=44921, objectId=7e264492131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e264492131, replyNumber=0, likeNumber=28, createdTime=2015-01-25, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e264492131, moduleTitle=2015年CRC行业的发展前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e264492131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827229, encodeId=8ad2182e22974, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, objectType=article, longId=40492, objectId=8caf404928a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caf404928a, replyNumber=0, likeNumber=35, createdTime=2015-04-01, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caf404928a, moduleTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caf404928a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827228, encodeId=3f5a182e2284d, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), objectType=article, longId=37048, objectId=c4a63e048dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a63e048dd, replyNumber=0, likeNumber=39, createdTime=2015-06-05, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a63e048dd, moduleTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4a63e048dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827224, encodeId=6782182e224da, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=受试者招募及其依从性管理 CRC的职责, objectType=article, longId=33862, objectId=29ee338626d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ee338626d, replyNumber=0, likeNumber=35, createdTime=2014-08-26, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ee338626d, moduleTitle=受试者招募及其依从性管理 CRC的职责, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ee338626d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, objectType=article, longId=20869, objectId=d9a32086951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9a32086951, replyNumber=0, likeNumber=48, createdTime=2013-07-18, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9a32086951, moduleTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9a32086951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827222, encodeId=f7d7182e22207, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=EPCRC发布首部癌症姑息治疗抑郁症管理指南, objectType=article, longId=2384, objectId=2ee9238459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ee9238459, replyNumber=0, likeNumber=35, createdTime=2011-09-14, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ee9238459, moduleTitle=EPCRC发布首部癌症姑息治疗抑郁症管理指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ee9238459)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CRC

2020-05-29

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Ann Intern Med：阿司匹林、NSAIDS与降低患CRC风险相关

2015-09-20

yxch36 (审核中...)

前往app查看评论内容

#CRC#

ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效

2015-07-18

yxch36 (审核中...)

前往app查看评论内容

#CRC#

现代临床研究亟待发展的一个角色：CRC

2015-10-24

yxch36 (审核中...)

前往app查看评论内容

#CRC#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2015-08-03

yxch36 (审核中...)

前往app查看评论内容

#CRC#

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2014-08-07

yxch36 (审核中...)

前往app查看评论内容

#CRC#

ASCO 2014：荟萃分析显示5FU一线双药化疗改善老年CRC的PFS

2014-05-27

yxch36 (审核中...)

前往app查看评论内容

#CRC#

ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？

2015-04-08

yxch36 (审核中...)

前往app查看评论内容

#CRC#

2015年CRC行业的发展前景

2015-01-25

yxch36 (审核中...)

前往app查看评论内容

#CRC#

CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待

2015-04-01

yxch36 (审核中...)

前往app查看评论内容

#CRC#

S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究)

2015-06-05

yxch36 (审核中...)

前往app查看评论内容

#CRC#

受试者招募及其依从性管理 CRC的职责

2014-08-26

yxch36 (审核中...)

前往app查看评论内容

#CRC#

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

2013-07-18

yxch36 (审核中...)

前往app查看评论内容

#CRC#

EPCRC发布首部癌症姑息治疗抑郁症管理指南

2011-09-14

科室
- - 订阅+
  - 更多科室
工具
服务